Hookipa: Hookipa Pharma Inc, a company originally founded in Austria, that develops a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform, started trading on the Nasdaq Global Select Market under theticker symbol “HOOK” on Thursday, April 18, 2019. The offering price was $14.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are around  $ 84 mn. The company plans to use the offering proceeds to advance HB-101, its lead product candidate in infectious diseases for the prevention of cytomegalovirus infections, through completion of the ongoing Phase 2 clinical trial, to advance HB-201 and HB-202, its lead oncology product candidates for cancers caused by human papilloma virus into and through completion of Phase 1 clinical trials, as well as to advance HB-301, its product candidate in metastatic, hormone-resistant prostate cancer into and through a Phase 1 clinical trial. Furthermore, HOOKIPA intends to further progress its earlier pipeline projects and ongoing research and development activities as well as for working capital and other general corporate purposes.